{"id":63931,"date":"2026-04-24T21:44:57","date_gmt":"2026-04-24T13:44:57","guid":{"rendered":"https:\/\/flcube.com\/?p=63931"},"modified":"2026-04-24T21:44:59","modified_gmt":"2026-04-24T13:44:59","slug":"insilico-medicine-advances-ai-designed-prmt5-inhibitor-ism0387-for-glioblastoma-with-sub-12-month-discovery-timeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63931","title":{"rendered":"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of <strong>ISM0387<\/strong> as a preclinical candidate (PCC). The novel compound was discovered by Insilico&#8217;s UAE team using the company&#8217;s proprietary <strong>Pharma.AI platform<\/strong> in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-discovery-milestone\">Drug Discovery Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insilico Medicine (HKG: 3696)<\/td><\/tr><tr><td><strong>Compound<\/strong><\/td><td>ISM0387<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical candidate (PCC)<\/td><\/tr><tr><td><strong>Discovery Team<\/strong><\/td><td>Insilico UAE team<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Proprietary Pharma.AI platform<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>Less than 12 months from target to PCC<\/td><\/tr><tr><td><strong>Molecular Class<\/strong><\/td><td>Novel-structure MTA-cooperative PRMT5 inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-profile-amp-mechanism\">Therapeutic Profile &amp; Mechanism<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-molecular-characteristics\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: PRMT5 (Protein Arginine Methyltransferase 5) with MTA-cooperative mechanism<\/li>\n\n\n\n<li><strong>Structure<\/strong>: AI-designed novel molecular architecture<\/li>\n\n\n\n<li><strong>Selectivity<\/strong>: Demonstrated good in vitro activity and selectivity profile<\/li>\n\n\n\n<li><strong>CNS Penetration<\/strong>: Optimized brain-penetrating properties for central nervous system delivery<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-preclinical-efficacy-data\">Preclinical Efficacy Data<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Models<\/strong>: Robust, dose-dependent efficacy demonstrated in glioblastoma models<\/li>\n\n\n\n<li><strong>Therapeutic Indication<\/strong>: Glioblastoma (GBM) &#8211; aggressive primary brain cancer<\/li>\n\n\n\n<li><strong>Clinical Rationale<\/strong>: Addresses critical unmet need in GBM treatment with limited therapeutic options<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Novel molecular structure combined with excellent CNS penetration capability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ai-platform-validation\">AI Platform Validation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pharma-ai-capabilities\">Pharma.AI Capabilities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>End-to-End Discovery<\/strong>: Complete drug discovery workflow from target identification to PCC<\/li>\n\n\n\n<li><strong>Geographic Flexibility<\/strong>: Successful implementation across international teams (UAE-based discovery)<\/li>\n\n\n\n<li><strong>Timeline Compression<\/strong>: Sub-12-month discovery cycle versus industry average of 4-6 years<\/li>\n\n\n\n<li><strong>Novel Chemistry<\/strong>: AI-generated molecular structures not previously conceived by human medicinal chemists<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Scalability<\/strong>: Demonstrates reproducible success across different therapeutic areas and geographies<\/li>\n\n\n\n<li><strong>Cost Efficiency<\/strong>: Dramatically reduced discovery costs through AI-driven target validation and compound design<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Proprietary algorithms enable first-in-class molecule generation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-next-steps\">Market Opportunity &amp; Next Steps<\/h2>\n\n\n\n<p>Glioblastoma represents one of oncology&#8217;s most challenging indications with median survival of approximately 15 months despite aggressive treatment. ISM0387&#8217;s combination of novel mechanism, CNS penetration, and robust preclinical efficacy positions it as a potential breakthrough therapy.<\/p>\n\n\n\n<p>Insilico Medicine will now advance ISM0387 through IND-enabling studies with the goal of initiating clinical trials within the next 18-24 months. The company&#8217;s established regulatory pathway experience with previous AI-discovered candidates provides confidence in successful clinical translation.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding drug development timelines, clinical trial initiation, and therapeutic potential. Actual clinical outcomes, regulatory approvals, and commercial success may differ based on clinical trial results, competitive developments, and regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042400296_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026042400296_c.\"><\/object><a id=\"wp-block-file--media-1cd92881-6251-4891-8526-15f9838f63f3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042400296_c.pdf\">2026042400296_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042400296_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1cd92881-6251-4891-8526-15f9838f63f3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,6],"tags":[99,4514,164,24],"class_list":["post-63931","post","type-post","status-publish","format-standard","hentry","category-company","category-rd","tag-ai","tag-hkg-3696","tag-insilico-medicine","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of ISM0387 as a preclinical candidate (PCC). The novel compound was discovered by Insilico&#039;s UAE team using the company&#039;s proprietary Pharma.AI platform in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63931\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of ISM0387 as a preclinical candidate (PCC). The novel compound was discovered by Insilico&#039;s UAE team using the company&#039;s proprietary Pharma.AI platform in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63931\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T13:44:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T13:44:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63931#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63931\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline\",\"datePublished\":\"2026-04-24T13:44:57+00:00\",\"dateModified\":\"2026-04-24T13:44:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63931\"},\"wordCount\":396,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"HKG: 3696\",\"Insilico Medicine\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"R&amp;D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63931#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63931\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63931\",\"name\":\"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-24T13:44:57+00:00\",\"dateModified\":\"2026-04-24T13:44:59+00:00\",\"description\":\"Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of ISM0387 as a preclinical candidate (PCC). The novel compound was discovered by Insilico's UAE team using the company's proprietary Pharma.AI platform in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63931#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63931\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63931#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of ISM0387 as a preclinical candidate (PCC). The novel compound was discovered by Insilico's UAE team using the company's proprietary Pharma.AI platform in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63931","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline","og_description":"Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of ISM0387 as a preclinical candidate (PCC). The novel compound was discovered by Insilico's UAE team using the company's proprietary Pharma.AI platform in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.","og_url":"https:\/\/flcube.com\/?p=63931","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-24T13:44:57+00:00","article_modified_time":"2026-04-24T13:44:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63931#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63931"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline","datePublished":"2026-04-24T13:44:57+00:00","dateModified":"2026-04-24T13:44:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63931"},"wordCount":396,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","HKG: 3696","Insilico Medicine","Rare \/ orphan disease drugs"],"articleSection":["Company","R&amp;D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63931#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63931","url":"https:\/\/flcube.com\/?p=63931","name":"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-24T13:44:57+00:00","dateModified":"2026-04-24T13:44:59+00:00","description":"Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection of ISM0387 as a preclinical candidate (PCC). The novel compound was discovered by Insilico's UAE team using the company's proprietary Pharma.AI platform in less than 12 months, representing a significant acceleration of traditional drug discovery timelines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63931#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63931"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63931#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63931"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63931\/revisions"}],"predecessor-version":[{"id":63933,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63931\/revisions\/63933"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}